Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin) in patient with non-resectable liver metastases from breast cancer. A phase II trial in patients with limited extrahepatic disease.

Trial Profile

Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin) in patient with non-resectable liver metastases from breast cancer. A phase II trial in patients with limited extrahepatic disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2017 Status changed from recruiting to completed.
    • 14 Jun 2013 Planned End Date changed from 1 Apr 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 07 Jul 2011 Planned End Date changed to 1 Apr 2014 from ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top